Paraquat Lawsuit 2026: Settlements, Claims & Payouts

Quick Answer Box

• What it is: A mass tort lawsuit against Syngenta and Chevron Phillips alleging paraquat herbicide exposure causes Parkinson's disease, consolidated in MDL 3004 in the Southern District of Illinois.
• Who qualifies: Agricultural workers, licensed applicators, and others with documented paraquat exposure who developed Parkinson's disease or parkinsonism.
• What it's worth: Individual payouts within the settlement matrix range from an estimated $100,000 to over $500,000, depending on exposure duration, disease severity, and diagnostic confirmation.

Case Snapshot

The paraquat lawsuit is one of the largest active agricultural chemical mass torts in the United States. At its core, it accuses two of the world's largest agrochemical companies of knowing their herbicide causes Parkinson's disease and selling it anyway.

As of 2026, the litigation is in settlement administration. That does not mean the case is over for everyone. Thousands of individual claims remain in processing, and new claimants continue evaluating their eligibility.

Here is something related: Minecraft Lawsuit 2026: Class Action Claims Explained

The scale of this case warrants serious attention. Over 5,000 federal cases were consolidated under MDL 3004 by 2023. The scientific record linking paraquat to Parkinson's is now robust enough that multiple federal courts have permitted it past summary judgment.

Understanding exactly where the litigation stands, what you can realistically expect from the settlement process, and when to act are the three things this piece is designed to answer.

What Is the Paraquat Lawsuit?

The paraquat lawsuit is a product liability mass tort alleging that long-term exposure to paraquat dichloride causes Parkinson's disease, and that manufacturers failed to warn users of that risk.

Paraquat dichloride is a fast-acting herbicide used primarily on soybeans, corn, wheat, and cotton. It has been in commercial use in the United States since the early 1960s. It is legally registered for use in the U.S. but is banned in the European Union and dozens of other countries due to its toxicity profile.

The lawsuits do not allege a single catastrophic event. They allege decades of occupational exposure to a product the defendants knew, or had reason to know, was neurologically harmful.

Key product names involved in claims:

• Gramoxone (Syngenta's primary brand)
• Para-Shot (Chevron Phillips)
• Firestorm (Chevron Phillips)
• Helmick-brand formulations (various distributors)

*Attorney Insight: Attorneys handling these claims consistently note that establishing the specific brand and product name the claimant used is one of the first documentation steps, because liability flows to the manufacturer of the specific formulation.*

Bold Callout: Paraquat is a Restricted Use Pesticide under the EPA. Only licensed applicators can legally purchase and apply it, which actually narrows and strengthens the plaintiff profile.

Is This a Paraquat Class Action Lawsuit?

The paraquat class action lawsuit framing is technically inaccurate. This litigation is a mass tort, not a true class action, though the distinction matters in ways most coverage fails to explain.

In a class action, one court certifies a defined group and resolves claims collectively under a single binding judgment. The paraquat litigation is structured differently. Each plaintiff retains their individual case, with individual damages tied to their specific exposure history and medical diagnosis.

What makes it resemble a class action is the MDL consolidation. All federal paraquat cases were consolidated before one judge, one court, and one discovery record. Pretrial proceedings are shared. But individual claim values are not shared.

*Attorney Insight: Attorneys in mass tort litigation emphasize that the individual-damages structure means no two payouts are the same, and that a strong medical record documenting disease progression directly affects case value.*

Bold Callout: Filing a paraquat claim is not the same as joining a class. You are initiating an individual personal injury action.

Paraquat Lawsuit Update 2026

The single most important 2026 development is that the global settlement framework established in late 2024 is now in active claims administration.

That framework resolved the largest bloc of filed cases. However, the administration process is ongoing. Claim review, documentation verification, and payout distribution are expected to continue through 2026 and into 2027 for later-filed claimants.

New cases continue to be evaluated for filing. Attorneys active in the MDL have not closed their intake. Potential claimants who have not yet filed are still being assessed, particularly those whose Parkinson's diagnoses are recent or whose exposure documentation took time to compile.

2026 Status Timeline:

*Attorney Insight: Attorneys monitoring the claims administration process note that documentation completeness, not just diagnosis, is currently the primary variable affecting how quickly individual claims move through the queue.*

Litigation Watch: The 2026 status of the paraquat lawsuit means the window to file is narrowing, the settlement fund is active, and claimants with documented exposure have more legal options available now than they will in 2027.

Understanding Paraquat MDL 3004

MDL 3004 is the federal multidistrict litigation docket number assigned to consolidated paraquat cases in the U.S. District Court for the Southern District of Illinois.

MDL stands for Multidistrict Litigation. When hundreds or thousands of federal cases share common factual and legal questions, the Judicial Panel on Multidistrict Litigation can consolidate them before a single judge for pretrial proceedings. That consolidation occurred here on June 3, 2021.

Judge Nancy J. Rosenstengel has presided over MDL 3004 from inception. She has overseen expert witness qualification disputes, summary judgment motions, and the bellwether trial selection process. Her rulings on general causation, specifically her decision allowing the plaintiffs' epidemiological and toxicological expert witnesses to testify, were a significant inflection point in the litigation.

MDL 3004 Key Facts:

• Court: U.S. District Court, Southern District of Illinois, East St. Louis Division
• Docket: MDL No. 3004, Case Management Order governing pretrial proceedings
• Judge: Hon. Nancy J. Rosenstengel
• Consolidation date: June 3, 2021
• Peak federal cases: Approximately 5,200+ at consolidation peak

*Attorney Insight: Attorneys note that MDL consolidation creates a shared discovery record, which benefits individual plaintiffs who lack the resources to conduct independent nationwide corporate discovery against a company the size of Syngenta.*

Bold Callout: MDL 3004 is not a class action. Individual cases retain their own identity and damages potential throughout the process.

Who Are the Defendants: Syngenta and Chevron Phillips?

The two primary defendants in the paraquat lawsuit are Syngenta AG and Chevron Phillips Chemical Company. Both manufactured and distributed paraquat-containing herbicides sold under several brand names across the United States.

Syngenta AG is a Swiss agrochemical conglomerate and the manufacturer of Gramoxone, the most widely recognized paraquat product sold in the American market. Syngenta has been majority-owned by ChemChina since 2017. Its U.S. subsidiary is named in most of the filed complaints. Syngenta's internal research documents, obtained through MDL discovery, have been central to plaintiffs' arguments that the company possessed internal data on paraquat's neurotoxic potential that was never communicated to end users.

Chevron Phillips Chemical Company manufactured Para-Shot and Firestorm. While its market share in the paraquat space was smaller than Syngenta's, it remains a named defendant in a significant portion of filed claims.

*Attorney Insight: Attorneys on the plaintiff side have built a significant portion of their failure-to-warn theory on internal Syngenta documents produced during MDL discovery, some of which trace back to internal research from the 1980s and 1990s.*

Bold Callout: Syngenta's Gramoxone accounts for the majority of brand-specific allegations in MDL 3004.

The Paraquat Parkinson's Disease Lawsuit: The Science Behind the Claims

The paraquat Parkinson's disease lawsuit rests on a body of scientific evidence that has been building since the 1980s and strengthened materially in the 2010s and 2020s.

Paraquat's chemical structure closely resembles MPP+, a compound that researchers at the National Institute of Environmental Health Sciences (NIEHS) demonstrated causes Parkinson's-like destruction of dopaminergic neurons in animal models. That structural similarity became the foundation for epidemiological research exploring human exposure outcomes.

Multiple peer-reviewed studies have established statistical associations between paraquat exposure and elevated Parkinson's disease risk. A landmark NIEHS-funded study published in the *American Journal of Epidemiology* found that people living within 500 meters of paraquat application fields had elevated Parkinson's disease incidence. A 2011 study found that paraquat exposure doubled the risk of Parkinson's disease compared to unexposed populations.

Key Scientific Findings Relevant to Claims:

• NIEHS Agricultural Health Study: Long-term cohort study of licensed pesticide applicators; found dose-dependent association between paraquat use and Parkinson's disease
• 2011 Risk Doubling Study: Published in *Environmental Health Perspectives*; found paraquat exposure doubled Parkinson's risk
• Mechanism: Paraquat generates reactive oxygen species that selectively damage substantia nigra dopaminergic neurons, the same neurons destroyed in Parkinson's disease

*Attorney Insight: Attorneys note that Judge Rosenstengel's decision in MDL 3004 to allow general causation expert testimony under Daubert standards was itself a validation of the scientific record, and that decision significantly strengthened plaintiff negotiating leverage going into settlement talks.*

How Paraquat Exposure Causes Parkinson's Disease: The Biological Link

The paraquat exposure Parkinson's link operates through a specific biological mechanism that courts in the MDL have now accepted as admissible scientific opinion.

Paraquat is absorbed through the skin, inhalation, and ingestion. Once in the bloodstream, it crosses the blood-brain barrier and concentrates in the substantia nigra, the midbrain region responsible for producing dopamine. It generates free radicals that cause oxidative stress specifically in dopaminergic neurons.

The destruction of these neurons is the defining pathological event in Parkinson's disease. By the time motor symptoms appear, a patient has typically lost 60 to 80 percent of their substantia nigra dopaminergic neurons.

Exposure routes relevant to claimant history:

• Direct mixing and loading of paraquat concentrate
• Spray application without adequate protective equipment
• Proximity to fields during or after application
• Dermal contact through contaminated equipment or clothing
• Inhalation of spray mist or drift

Bold Callout: Researchers have found that even low-level chronic exposure carries elevated Parkinson's risk, which extends eligibility beyond high-volume commercial applicators to casual or seasonal agricultural workers.

*Attorney Insight: Attorneys evaluating claims pay close attention to whether the claimant mixed the concentrate, a task associated with the highest dermal and inhalation exposure, versus whether they performed post-application field work.*

Litigation Watch: The scientific case linking paraquat to Parkinson's disease has passed federal admissibility review under Daubert standards in MDL 3004, which was the pivotal moment that moved defendants toward settlement.

Who Qualifies for the Paraquat Lawsuit?

Eligibility for the paraquat lawsuit requires two core elements: documented exposure to a paraquat-containing product and a diagnosis of Parkinson's disease or parkinsonism.

Exposure documentation is the first threshold. Courts and claims administrators require evidence that the claimant actually used, handled, or was regularly in proximity to paraquat. Purchasing records, pesticide application licenses, employment records with agricultural employers, and physician records noting occupational pesticide exposure are all relevant.

Medical diagnosis is the second threshold. A confirmed Parkinson's disease diagnosis from a neurologist carries the most weight. Parkinsonism diagnoses (a broader category of Parkinson's-like neurological conditions) may qualify depending on the specific claims administrator's criteria, but they typically fall into a lower compensation tier.

Something similar worth reading: Class Action Lawsuit List: Active Cases & Payouts 2026

General Eligibility Criteria:

*Attorney Insight: Attorneys screening new clients note that the combination of a pesticide applicator license history and a Parkinson's disease diagnosis from a movement disorder specialist represents the strongest possible claim profile.*

Paraquat Lawsuit Eligibility: Who Is Most Likely to Qualify?

Paraquat lawsuit eligibility extends beyond full-time farm workers to include a wider range of agricultural and commercial applicators.

The EPA's Restricted Use classification means that legal purchasers and applicators are documented in state pesticide licensing records. That paper trail is actually beneficial to claimants. It creates a contemporaneous record of exposure that predates any litigation.

Occupational categories most represented in MDL 3004:

• Licensed pesticide applicators (commercial and agricultural)
• Farm owners and operators who applied paraquat themselves
• Farm laborers who mixed, loaded, or applied product
• Golf course and turf management workers (Gramoxone was used in turf settings)
• Nursery and greenhouse workers
• Railroad right-of-way maintenance workers
• Utility corridor vegetation management workers

Those less likely to qualify:

• Homeowners (paraquat is not available for residential consumer purchase)
• Individuals with no documented proximity to agricultural or commercial application
• People with Parkinson's diagnoses not reasonably connected to exposure timing

*Attorney Insight: Attorneys note that residential proximity claims, people who lived near fields where paraquat was applied, have been advanced in the litigation, but they face a higher documentation burden than direct occupational applicators.*

Bold Callout: Individuals whose Parkinson's disease was diagnosed within five to twenty years of regular paraquat exposure represent the core of the plaintiff pool in MDL 3004.

The Paraquat Farm Worker Lawsuit: Geographic and Occupational Concentration

The paraquat farm worker lawsuit reflects the geographic reality of where paraquat was used most heavily in American agriculture.

California's San Joaquin Valley, the Midwest soybean and corn belt (Illinois, Iowa, Indiana, Ohio), the Mississippi Delta cotton region, and the southeastern tobacco growing states represent the highest concentrations of historical paraquat use. Not coincidentally, these are also the regions where plaintiff-side law firms have concentrated their claim intake operations.

Illinois is particularly significant for procedural reasons. MDL 3004 sits in the Southern District of Illinois. That jurisdiction covers East St. Louis and Benton, areas surrounded by some of the most paraquat-intensive agricultural land in the country.

States with Highest Claimant Concentration in MDL 3004:

*Attorney Insight: Attorneys based in agricultural states have noted that migrant farm worker populations represent a significantly underserved segment of potential claimants, partly due to documentation gaps and partly due to limited legal system access.*

Paraquat Settlement 2026: Where Does the Fund Stand?

The paraquat settlement 2026 status reflects a litigation that resolved its core liability dispute and is now in the distribution phase of a confirmed global framework.

The $187.5 million settlement framework announced in 2024 was structured to resolve the largest volume of then-pending federal claims. Settlement funds of this scale in mass tort litigation are administered through a claims management process, not a simple check distribution. Each claimant's payout is calculated through a settlement matrix that weighs specific variables.

The claims administrator appointed under the MDL framework is responsible for reviewing submitted documentation, assigning point values within the matrix, and generating individual award recommendations.

Settlement Administration Timeline (2026):

*Attorney Insight: Attorneys advising clients currently in the claims administration process emphasize that incomplete documentation is the primary cause of claims being placed in a secondary review queue, which delays payment.*

Bold Callout: The $187.5 million framework represents the initial resolution layer. Additional funds may be required if claim volume exceeds initial projections.

Litigation Watch: The paraquat settlement 2026 is in active distribution, but the process is not instantaneous. Claimants with complete documentation packages receive determinations faster than those still gathering records.

What Are Typical Paraquat Lawsuit Settlement Amounts?

Paraquat lawsuit settlement amounts vary significantly depending on where a claimant falls within the settlement matrix.

No official per-claimant figure has been publicly issued by the court or the claims administrator as of mid-2026. Settlement matrices in mass tort cases are typically confidential. However, litigation analysts tracking MDL 3004 have estimated individual awards based on public filings and comparable mass tort outcomes.

Estimated Payout Ranges by Claim Tier:

*Attorney Insight: Attorneys note that cases involving younger onset Parkinson's disease, diagnoses before age 60, may carry higher valuation due to greater lifetime impact and stronger causation presumptions.*

Bold Callout: Attorney fees in mass tort cases are typically contingency-based at 33 to 40 percent of the gross award, and litigation costs are usually deducted before the attorney fee is applied.

Paraquat Settlement Payout Per Person: How Is the Amount Calculated?

Paraquat settlement payout per person is determined through a matrix system that assigns numerical point values to specific medical, exposure, and demographic variables.

The matrix approach is standard in large-scale mass tort settlements. It replaces individual jury trials with an administrative scoring system designed to value claims consistently. Points are assigned for duration of exposure, frequency of contact, severity of Parkinson's disease at time of claim, age of onset, and impact on daily functioning.

Key Variables That Increase Individual Award:

• Longer documented exposure history (years of application records)
• Higher frequency of contact (mixing concentrate vs. indirect proximity)
• Confirmed Parkinson's disease diagnosis from a movement disorder specialist
• Earlier age of Parkinson's onset (below age 65 at diagnosis)
• Greater functional impairment (advanced Hoehn and Yahr scale rating)
• Clear product identification (specific brand, specific years of use)

Variables That May Reduce Individual Award:

• Parkinsonism diagnosis rather than Parkinson's disease
• Minimal documented exposure (few records, short duration)
• Confounding diagnoses (conditions that may explain motor symptoms independently)
• Late-stage claims filed after primary settlement wave

*Attorney Insight: Attorneys working with movement disorder specialists note that a formal Hoehn and Yahr staging evaluation, a standard Parkinson's disease severity scale, is often submitted as part of the claims package to support higher-tier placement.*

Paraquat Class Action vs. Mass Tort: What You Need to Know

The paraquat class action vs. mass tort distinction directly affects how your case is valued and how you receive compensation.

A true class action consolidates all plaintiffs into one lawsuit with one outcome. Paraquat litigation is not a class action. It is a mass tort consolidated under MDL procedures. Each plaintiff retains a legally distinct claim. The MDL structure benefits plaintiffs by sharing the enormous cost of scientific expert witnesses and corporate discovery across thousands of cases simultaneously.

The practical consequence is that two claimants with identical diagnoses but different exposure histories may receive substantially different payouts. The individualized nature of the settlement matrix reflects this reality.

Why This Matters for Potential Claimants:

• You must actively file your own claim or retain counsel to file on your behalf
• Doing nothing does not make you part of any settlement
• Your individual records directly determine your individual award
• Stronger documentation produces stronger outcomes

*Attorney Insight: Attorneys compare the MDL structure to a coordinated military campaign where logistics are shared but each unit fights its own engagement. The benefit of shared discovery is significant; the responsibility to document your own case remains fully with you.*

Bold Callout: You are not automatically included in any paraquat settlement simply because you have Parkinson's disease and a history of paraquat exposure. Active filing is required.

See also: Minecraft Lawsuit 2026: Class Action, Claims and Payouts

Litigation Watch: The distinction between a class action and a mass tort is not semantic; it determines whether you receive an individual evaluated payout or nothing at all, which is why taking no action is the worst possible outcome for a potential claimant.

Paraquat Lawsuit Filing Deadline 2026: What Are the Deadlines?

The paraquat lawsuit filing deadline 2026 is governed by both the statute of limitations in the state where exposure occurred and by case management orders within MDL 3004.

Statutes of limitations for personal injury claims vary by state. Most states allow two to four years from the date of injury discovery. In toxic exposure cases, discovery is typically defined as the date a plaintiff knew or reasonably should have known that their Parkinson's disease was linked to pesticide exposure, not the date of exposure itself.

Statute of Limitations by Key States:

The MDL also operates under case management deadlines. While general case filing through the MDL was not formally closed as of early 2026, courts managing settlement administration may impose cut-off dates for participation in the primary settlement tranche.

*Attorney Insight: Attorneys consistently advise that waiting for a formal announced deadline before contacting counsel is the highest-risk strategy. By the time a cut-off date is publicly announced, filing capacity may be limited.*

Bold Callout: The safest assumption for any potential claimant in 2026 is that time is measurably limited. The primary settlement wave is already in distribution.

How to File a Paraquat Lawsuit

Filing a paraquat lawsuit requires retaining a qualified plaintiff's attorney who handles mass tort product liability cases. This is not a form-based self-filing process.

The first step is a case evaluation. Attorneys handling paraquat claims conduct intake interviews to assess exposure history, product identification, and medical diagnosis. That evaluation is almost universally free of charge and non-binding.

If the attorney accepts the case, they prepare and file a Short Form Complaint through the MDL's administrative process, adopting the Master Long Form Complaint on file in MDL 3004. The attorney then manages discovery responses, medical record collection, and claims administrator submission on the client's behalf.

Steps to File a Paraquat Lawsuit in 2026:

1. Identify your exposure history: Dates, products used, employer records, pesticide license documentation
2. Gather medical records: Parkinson's disease diagnosis, neurologist records, movement disorder specialist evaluations
3. Contact a mass tort attorney: Choose a firm with documented MDL 3004 experience, not a general personal injury practice
4. Case evaluation: Attorney reviews exposure and medical profile at no cost
5. Attorney files complaint: Short Form Complaint filed through MDL 3004 process
6. Claims administrator submission: Medical and exposure documentation submitted per settlement framework requirements
7. Award determination: Claims administrator assigns matrix tier and calculates individual award

*Attorney Insight: Attorneys recommend that claimants request their complete pesticide applicator license history from their state department of agriculture as early as possible, because that database represents contemporaneous official exposure documentation that is difficult to dispute.*

Bold Callout: Contingency fee representation means you pay no upfront legal fees. Attorney compensation comes only from a successful recovery.

Frequently Asked Questions

What is the paraquat lawsuit about?

The paraquat lawsuit is a product liability mass tort against Syngenta and Chevron Phillips alleging that paraquat herbicide exposure causes Parkinson's disease.

Plaintiffs allege the companies knew of this risk and failed to warn users.

The litigation is consolidated in MDL 3004 in the Southern District of Illinois before Judge Nancy J. Rosenstengel.

Who qualifies for the paraquat class action lawsuit?

Qualifying claimants generally include agricultural workers, licensed pesticide applicators, and others with documented paraquat exposure who developed Parkinson's disease.

Exposure must have occurred in the United States, and a confirmed neurological diagnosis is required.

Parkinsonism diagnoses may qualify at a lower compensation tier depending on claims administrator criteria.

How much is the paraquat settlement payout per person in 2026?

Individual payouts are estimated between $100,000 and $500,000+ depending on exposure duration, disease severity, and diagnostic documentation.

No official per-claimant figure has been publicly disclosed by the claims administrator.

Tier placement within the settlement matrix is the primary determinant of award size.

What is MDL 3004 and which court oversees it?

MDL 3004 is the federal multidistrict litigation docket consolidating paraquat cases in the U.S. District Court for the Southern District of Illinois.

Judge Nancy J. Rosenstengel has presided over the MDL since its establishment on June 3, 2021.

The MDL coordinates pretrial proceedings for all federal paraquat cases while preserving individual claim identity and damages.

What is the filing deadline for a paraquat lawsuit in 2026?

There is no single universal deadline. Applicable statutes of limitations vary by state, typically running two to four years from the discovery date of the paraquat-Parkinson's connection.

MDL case management orders may impose separate participation cut-off dates for the primary settlement tranche.

Any potential claimant should consult a mass tort attorney immediately rather than waiting for a formal announced deadline.

How do I find a paraquat lawsuit attorney?

Seek an attorney or firm with documented experience in MDL 3004 specifically, not a general personal injury practice.

Mass tort plaintiff firms handling paraquat cases conduct free case evaluations with no upfront fees.

State bar referral services and national legal authority directories can identify attorneys with the specific mass tort credentials this litigation requires.

Closing

The paraquat lawsuit is not winding down in 2026. It is in the distribution phase of an active settlement, and new claims are still being evaluated. The window is not closed, but it is narrowing in measurable ways.

Anyone with documented paraquat exposure and a Parkinson's disease diagnosis should treat 2026 as an action year, not a waiting year. The settlement matrix rewards documentation completeness and early submission.

If you or someone in your household has a relevant exposure history and a qualifying diagnosis, the appropriate next step is a formal case evaluation with an attorney who has active involvement in MDL 3004. That evaluation costs nothing and produces a clear answer about where you stand.

Related resource: GOLO Lawsuit 2026: Claims, Settlement & Who Qualifies